Merck price target raised to $130 from $128 at Barclays

Barclays analyst Carter Gould raised the firm’s price target on Merck to $130 from $128 and keeps an Overweight rating on the shares post the Q1 results. The analyst says Gardasil and Keytruda momentum provide near-term upside.